3/3
10:52 pm
allo
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]
Neutral
Report
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]
3/2
08:54 am
allo
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update [Yahoo! Finance]
Low
Report
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update [Yahoo! Finance]
3/2
08:30 am
allo
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Low
Report
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
2/22
02:02 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at
Wall Str
Low
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at
Wall Str
2/5
08:30 am
allo
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Medium
Report
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
1/29
11:12 pm
allo
??·?????????????????2035????1,831????????????????? [CNET News]
High
Report
??·?????????????????2035????1,831????????????????? [CNET News]
1/9
11:12 am
allo
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? [Yahoo! Finance]
Medium
Report
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? [Yahoo! Finance]
1/9
08:42 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "mkt outperform" rating. They now have a $5.00 price target on the stock.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "mkt outperform" rating. They now have a $5.00 price target on the stock.
1/9
07:00 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
1/9
06:10 am
allo
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
1/8
09:06 am
allo
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T [Yahoo! Finance]
Low
Report
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T [Yahoo! Finance]
1/8
08:30 am
allo
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
Low
Report
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
1/7
09:07 am
allo
Allogene Therapeutics (NASDAQ:ALLO) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Allogene Therapeutics (NASDAQ:ALLO) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
12/15
06:21 pm
allo
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis [Yahoo! Finance]
12/15
05:39 pm
allo
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
Medium
Report
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis